We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+6.5%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$308M
AUM Growth
-$38.9M
Cap. Flow
-$25.7M
Cap. Flow %
-8.35%
Top 10 Hldgs %
52.97%
Holding
98
New
10
Increased
19
Reduced
20
Closed
18

Top Buys

Rank Stock Value
1
IDYA icon
IDEAYA Biosciences
IDYA
+$4.11M
2
ARCT icon
Arcturus Therapeutics
ARCT
+$4M
3
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$2.94M
4
ETNB
89bio
ETNB
+$2.85M
5
ASND icon
Ascendis Pharma A/S
ASND
+$2.16M

Top Sells

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$11.3M
2
KURA icon
Kura Oncology
KURA
+$5.64M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$3.92M
4
CGEN icon
Compugen
CGEN
+$3.73M
5
AKBA icon
Akebia Therapeutics
AKBA
+$3.69M

Sector Composition

Rank Sector Weight
1 Healthcare 83.1%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STRO icon
51
Sutro Biopharma
STRO
$421M
$1.2M 0.39%
11,894
+1,250
+12% +$118K
PHAS
52
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$1.13M 0.37%
320,542
– –
SPRO icon
53
Spero Therapeutics
SPRO
$73M
$1.12M 0.36%
+100,000
New +$1.18M
VRNA
54
DELISTED
Verona Pharma
VRNA
$1.01M 0.33%
+161,507
New +$1.12M
APLS
55
DELISTED
Apellis Pharmaceuticals
APLS
$907K 0.29%
30,054
-3,500
-10% -$105K
AKBA icon
56
Akebia Therapeutics
AKBA
$252M
$858K 0.28%
341,779
-420,887
-55% -$3.69M
ACET icon
57
Adicet Bio
ACET
$74.7M
$803K 0.26%
+4,224
New +$1.07M
SIOX
58
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$790K 0.26%
171,083
-834,308
-83% -$2.75M
MDGL icon
59
Madrigal Pharmaceuticals
MDGL
$11.8B
$784K 0.25%
6,600
– –
PRVL
60
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$764K 0.25%
75,000
– –
ARDX icon
61
Ardelyx
ARDX
$997M
$759K 0.25%
144,650
-40,200
-22% -$242K
NXTC icon
62
NextCure
NXTC
$26.7M
$748K 0.24%
7,083
+5,416
+325% +$666K
NTUS
63
DELISTED
Natus Medical Inc
NTUS
$735K 0.24%
42,900
– –
KRTX
64
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$714K 0.23%
9,231
– –
MASI
65
DELISTED
Masimo
MASI
$708K 0.23%
3,000
– –
SCPH
66
DELISTED
scPharmaceuticals
SCPH
$677K 0.22%
90,900
-9,100
-9% -$71.1K
DMAC icon
67
DiaMedica Therapeutics
DMAC
$364M
$664K 0.22%
+156,529
New +$828K
CHMA
68
DELISTED
Chiasma, Inc. Common Stock
CHMA
$659K 0.21%
+153,208
New +$734K
ASMB icon
69
Assembly Biosciences
ASMB
$529M
$585K 0.19%
2,964
– –
GMDA
70
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$581K 0.19%
140,000
– –
MREO
71
Mereo BioPharma
MREO
$47.3M
$522K 0.17%
199,425
+122,625
+160% +$358K
ZYME icon
72
Zymeworks
ZYME
$1.67B
$463K 0.15%
9,950
-8,089
-45% -$278K
INGN icon
73
Inogen
INGN
$164M
$435K 0.14%
15,000
– –
RDUS
74
DELISTED
Radius Health, Inc.
RDUS
$249K 0.08%
22,000
– –
HOOK
75
DELISTED
HOOKIPA Pharma
HOOK
$209K 0.07%
2,206
-5,806
-72% -$592K
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return
BCM
Beck Capital Management Austin, Texas $437M AUM 59.35% 1-Year Est. Return

DAFNA Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, DAFNA Capital Management held 98 positions worth $308M, down 11% from $347M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

DAFNA Capital Management withdrew a net $25.7M in Q3 2020, closing 18 positions and reducing 20 holdings. Its most notable exit was Mirati Therapeutics, Inc. Common Stock, an estimated $2.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 88% a quarter earlier, followed by Financials.

Against the trend, DAFNA Capital Management opened a new position in IDEAYA Biosciences worth $4.17M.

  • DAFNA Capital Management's largest Q3 2020 buy was IDEAYA Biosciences: 331,661 shares worth $4.17M.
  • DAFNA Capital Management added most to Arcturus Therapeutics in Q3 2020, an estimated $4M increase.
  • DAFNA Capital Management's biggest Q3 2020 reduction was Arena Pharmaceuticals Inc, cutting an estimated $11.3M.
  • DAFNA Capital Management fully exited Mirati Therapeutics, Inc. Common Stock in Q3 2020, selling an estimated $2.5M.
  • DAFNA Capital Management's ten largest holdings make up 53% of its $308M portfolio in Q3 2020.
  • DAFNA Capital Management opened 10 new positions and closed 18 in Q3 2020.
  • DAFNA Capital Management's portfolio value fell 11% quarter-over-quarter to $308M.

Based on DAFNA Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.